Arab Finance: Macro Group Pharmaceutical (Macro Capital) recorded EGP 88.799 million in consolidated net losses attributable to the parent company during the first half (H1) of 2024, compared to EGP 29.338 million in net profits in H1 2023, as per a filing.

Sales fell to EGP 155.252 million in H1 2024 from EGP 337.235 million in H1 2023.

Likewise, the company registered EGP 86.12 million in standalone net losses after tax in the six months to June, versus net profits of EGP 30.337 million in the same period last year.

Meanwhile, standalone sales went down to EGP 155.14 million from EGP 337.106 million.

Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.

Maridive turns to profits in H1 2024 Updated 9/16/2024 1:48:00 PM

Al Khair River’s standalone profits surge 60.9% YoY in H1 2024 Updated 9/16/2024 2:39:00 AM

Ezz Steel moves to profits in H1 2024 Updated 9/11/2024 10:04:00 AM

Golden Pyramids’ consolidated profits surge 552.4% YoY in Q1 2024 Updated 9/8/2024 10:35:00 AM

IFAP’s consolidated profits up 18% YoY in FY2023/24 Updated 9/4/2024 10:22:00 AM